Aleglitazar
Aleglitazar is a pharmaceutical drug that was developed as a dual peroxisome proliferator-activated receptor (PPAR) agonist, targeting both the PPAR_ and PPAR_ subtypes. It was investigated for its potential use in the treatment of type 2 diabetes mellitus and associated cardiovascular disease.
Mechanism of Action[edit]
Aleglitazar functions by activating the PPAR_ and PPAR_ receptors, which play key roles in the regulation of lipid metabolism and glucose homeostasis. Activation of PPAR_ leads to increased fatty acid oxidation and improved lipid profile, while PPAR_ activation enhances insulin sensitivity and glucose uptake in adipose tissue.
Development and Clinical Trials[edit]
Aleglitazar was developed by Hoffmann-La Roche and underwent several phases of clinical trials. The drug showed promise in early studies by improving glycemic control and lipid parameters in patients with type 2 diabetes. However, later-stage trials raised concerns about its safety profile, particularly regarding heart failure and renal impairment.
Safety and Efficacy[edit]
The safety concerns observed in clinical trials included an increased risk of congestive heart failure, bone fractures, and renal dysfunction. These adverse effects led to the discontinuation of its development for the treatment of type 2 diabetes.
Conclusion[edit]
Despite its initial promise as a dual PPAR agonist, Aleglitazar's development was halted due to safety concerns. The case of Aleglitazar highlights the challenges in developing drugs that target multiple pathways and the importance of thorough safety evaluations in the drug development process.
Related Pages[edit]
Sponsored Health Resource
W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
Medical weight loss NYC | Affordable GLP-1 injections NYC | Budget GLP-1 weight loss shots Philadelphia | New Jersey medical weight loss | NYC medical weight loss | Philadelphia medical weight loss | Sleep clinic NYC | W8MD's Philadelphia GLP-1 doctor | Weight loss prescriptions NYC
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
